# Breast Cancer Breast cancer is the most extensively studied tumour setting in the berberine literature. That matters because the research is not limited to one subtype. Berberine has been studied across **triple-negative**, **ER-positive**, and **HER2-positive** models, with different mechanisms standing out in each. ### Related treatment context If the practical question is **ER-positive, HER2-negative** disease on **abemaciclib** or **ribociclib**, also see [CDK4/6 Options and Supplement Considerations](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations.md). That page covers where berberine may sit around CDK4/6 therapy, and where the interaction burden becomes the bigger issue. ### Why berberine stands out here Breast cancer shows the widest subtype spread in the berberine evidence base. The main themes are: * apoptosis and cell-cycle arrest * endocrine sensitisation * radiosensitisation * ferroptosis relevance * EMT and metastasis suppression * reversal of targeted-therapy resistance in selected HER2-positive models ### Triple-negative breast cancer TNBC is one of the strongest berberine settings because it lacks many of the targeted options available in other subtypes. Reported findings include: * growth inhibition across multiple TNBC cell lines * subtype-dependent cell-cycle arrest * activation of caspases and PARP cleavage * radiosensitisation * **ferroptosis induction** in selected models * broad glycolysis suppression through the **LH2 / PKM2 / LDHA** network * reversal of EMT-related behaviour This gives TNBC one of the clearest multi-mechanism rationales for berberine. ### ER-positive / luminal breast cancer In ER-positive breast cancer, berberine has shown both direct activity and combination relevance. The main findings include: * **G1 arrest** in MCF-7 cells * a shift in the **BAX/BCL-2** balance toward apoptosis * modulation of the **miR-203 / Bcl-w** axis * sensitisation to **tamoxifen**, including resistant variants in preclinical models That makes ER-positive disease one of the stronger settings for berberine as an endocrine-sensitising adjunct under investigation. ### HER2-positive breast cancer The key berberine finding here is **lapatinib resistance reversal**. In resistant HER2-positive models, berberine increased ROS and weakened the tumour's antioxidant protection through **Nrf2-related** signalling changes. That is one of the clearest examples in the literature of berberine helping dismantle a targeted-therapy resistance shield. ### Broader breast-cancer themes Across breast-cancer models, berberine has also shown: * reduced metastatic signalling through **MMP** suppression and **E-cadherin** support * reduced cancer stem-like behaviour * multi-pathway effects that cross subtype boundaries ### Practical interpretation Breast cancer is berberine's most nuanced tumour-specific page. The strongest current rationale differs by subtype: * **TNBC:** ferroptosis, radiosensitisation, metabolic pressure, and anti-EMT activity * **ER-positive:** tamoxifen sensitisation and apoptosis support * **HER2-positive:** reversal of lapatinib resistance via ROS and Nrf2-linked mechanisms This is still a preclinical evidence base. Even so, breast cancer is one of the best-developed areas for understanding how berberine might be matched to tumour biology. ### References ### Breast Cancer — TNBC ⭐⭐⭐⭐ Multi-cell-line activity and subtype-specific mechanisms: Mukherjee S, et al. (2020). Berberine Impairs the Survival of Triple Negative Breast Cancer Cells: A Comparison with Cisplatin and Illustration of Different Mechanistic Profiles. Nutrition and Cancer, 72(2):774–790.\ 🔗 ]\() Radiosensitisation via LIGIII/DNA repair: (2025). Berberine Sensitises Breast Cancer Cells to Radiation via the Impairment of DNA Repair through LIGIII. International Journal of Molecular Sciences (PMC).\ 🔗 ]\() *** ### Breast Cancer — ER+ ⭐⭐⭐⭐ Tamoxifen sensitisation and comprehensive subtype review: Ahmad F, et al. (2022). Berberine as a potential agent for breast cancer therapy. Frontiers in Pharmacology / PMC review.\ 🔗 ]\() *** ### Breast Cancer — HER2+ ⭐⭐⭐ Lapatinib resistance reversal via Nrf2/ROS: (Covered within the broader Nrf2 inhibitors in cancer therapy review)\ Robledinos-Antón N, et al. (2019). Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative Medicine and Cellular Longevity.\ 🔗 {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/breast-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.